Obesity	obesity	NN	O
is	be	VBZ	O
characterised	characterise	VBN	O
by	by	IN	O
abnormal	abnormal	JJ	O
fat	fat	NN	O
accumulation	accumulation	NN	O
due	due	IN	O
to	to	IN	O
a	a	DT	O
systemic	systemic	JJ	O
dysfunction	dysfunction	NN	O
of	of	IN	O
energy	energy	NN	O
homeostasis	homeostasis	NN	O
.	.	.	O

It	-PRON-	PRP	O
is	be	VBZ	O
a	a	DT	O
significant	significant	JJ	O
risk	risk	NN	O
factor	factor	NN	O
for	for	IN	O
diabetes	diabetes	NN	O
,	,	,	O
hypertension	hypertension	NN	O
,	,	,	O
cardiovascular	cardiovascular	JJ	O
disease	disease	NN	O
,	,	,	O
and	and	CC	O
non	non	JJ	O
-	-	JJ	O
alcoholic	alcoholic	JJ	O
fatty	fatty	NN	O
liver	liver	NN	O
disease	disease	NN	B
.	.	.	O

Excessive	excessive	JJ	O
accumulation	accumulation	NN	O
of	of	IN	O
triglycerides	triglyceride	NNS	O
in	in	IN	O
adipocytes	adipocyte	NNS	O
and	and	CC	O
non	non	NNS	O
-	-	NNS	O
adipocytes	adipocyte	NNS	O
,	,	,	O
including	include	VBG	O
in	in	IN	O
the	the	DT	O
liver	liver	NN	O
,	,	,	O
skeletal	skeletal	JJ	O
muscle	muscle	NN	O
,	,	,	O
myocardium	myocardium	NN	O
,	,	,	O
and	and	CC	O
pancreas	pancreas	NN	O
,	,	,	O
is	be	VBZ	O
a	a	DT	O
crucial	crucial	JJ	O
feature	feature	NN	O
of	of	IN	O
obesity	obesity	NN	B
.	.	.	O

In	in	IN	O
particular	particular	JJ	O
,	,	,	O
abnormal	abnormal	JJ	O
TAG	TAG	NNP	O
levels	level	NNS	O
increases	increase	VBZ	O
the	the	DT	O
risk	risk	NN	O
of	of	IN	O
metabolic	metabolic	JJ	O
syndrome	syndrome	NN	O
,	,	,	O
characterised	characterise	VBN	O
by	by	IN	O
as	as	IN	O
insulin	insulin	NN	O
resistance	resistance	NN	O
,	,	,	O
dyslipidemia	dyslipidemia	NN	O
and	and	CC	O
cardiomyopathy	cardiomyopathy	JJ	B
.	.	.	O

Therefore	therefore	RB	O
,	,	,	O
preventing	prevent	VBG	O
excessive	excessive	JJ	O
accumulation	accumulation	NN	O
of	of	IN	O
TAG	TAG	NNP	O
could	could	MD	O
be	be	VB	O
beneficial	beneficial	JJ	O
in	in	IN	O
the	the	DT	O
treatment	treatment	NN	O
of	of	IN	O
metabolic	metabolic	JJ	O
diseases	disease	NNS	O
such	such	JJ	O
as	as	IN	O
obesity	obesity	NN	O
and	and	CC	O
type	type	NN	O
2	2	CD	O
diabetes	diabetes	NN	O
.	.	.	O

Two	two	CD	O
routes	route	NNS	O
of	of	IN	O
TAG	TAG	NNP	O
biosynthesis	biosynthesis	NN	O
have	have	VBP	O
been	be	VBN	O
identified	identify	VBN	O
:	:	:	O
the	the	DT	O
glycerol	glycerol	NNP	O
phosphate	phosphate	NNP	O
pathway	pathway	NNP	O
,	,	,	O
and	and	CC	O
the	the	DT	O
monoacylglycerol	monoacylglycerol	JJ	O
pathway	pathway	JJ	B
.	.	.	O

Both	both	DT	O
routes	route	NNS	O
have	have	VBP	O
a	a	DT	O
common	common	JJ	O
intermediate	intermediate	JJ	O
,	,	,	O
diacylglycerol	diacylglycerol	NN	O
,	,	,	O
which	which	WDT	O
is	be	VBZ	O
then	then	RB	O
converted	convert	VBN	O
to	to	IN	O
TAG	TAG	NNP	O
by	by	IN	O
acyl	acyl	NNP	O
CoA	CoA	NNP	O
:	:	:	O
diacylglycerol	diacylglycerol	VB	O
acyltransferase	acyltransferase	JJ	B
.	.	.	O

DGAT	dgat	NN	O
exists	exist	VBZ	O
as	as	IN	O
two	two	CD	O
isoforms	isoform	NNS	O
,	,	,	O
DGAT-1	DGAT-1	NNS	O
and	and	CC	O
DGAT-2	dgat-2	NN	O
,	,	,	O
which	which	WDT	O
share	share	VBP	O
minimal	minimal	JJ	O
sequence	sequence	NN	O
homology	homology	NN	B
.	.	.	O

These	these	DT	O
enzymes	enzyme	NNS	O
catalyse	catalyse	VBP	O
the	the	DT	O
final	final	JJ	O
dedicated	dedicated	JJ	O
step	step	NN	O
in	in	IN	O
TAG	TAG	NNP	O
synthesis	synthesis	NN	O
:	:	:	O
i.e.	i.e.	FW	O
the	the	DT	O
esterification	esterification	NN	O
of	of	IN	O
a	a	DT	O
fatty	fatty	NN	O
acid	acid	NN	O
moiety	moiety	NN	O
to	to	IN	O
DAG	DAG	NNP	O
to	to	TO	O
generate	generate	VB	O
TAG	TAG	NNP	O
.	.	.	O

DGAT-1	DGAT-1	NNP	O
is	be	VBZ	O
highly	highly	RB	O
expressed	express	VBN	O
in	in	IN	O
the	the	DT	O
small	small	JJ	O
intestine	intestine	NN	O
,	,	,	O
adipose	adipose	JJ	O
tissue	tissue	NN	O
,	,	,	O
and	and	CC	O
liver	liver	VB	B
.	.	.	O

DGAT-1	DGAT-1	NNS	O
deficient	deficient	JJ	O
mice	mouse	NNS	O
showed	show	VBD	O
a	a	DT	O
significant	significant	JJ	O
reduction	reduction	NN	O
in	in	IN	O
the	the	DT	O
postprandial	postprandial	JJ	O
increase	increase	NN	O
of	of	IN	O
plasma	plasma	NN	O
TAG	TAG	NNP	O
and	and	CC	O
were	be	VBD	O
resistant	resistant	JJ	O
to	to	IN	O
diet	diet	VB	O
-	-	HYPH	O
induced	induce	VBN	O
obesity	obesity	NN	O
due	due	JJ	O
to	to	IN	O
increased	increase	VBN	O
energy	energy	NN	O
expenditure	expenditure	NN	O
.	.	.	O

Moreover	moreover	RB	O
,	,	,	O
the	the	DT	O
DGAT1	DGAT1	NNP	O
knockout	knockout	NNP	O
mice	mouse	NNS	O
had	have	VBD	O
enhanced	enhance	VBN	O
sensitivity	sensitivity	NN	O
to	to	TO	O
insulin	insulin	NN	O
and	and	CC	O
leptin	leptin	NN	O
.	.	.	O

Indeed	indeed	RB	O
,	,	,	O
DGAT-1	DGAT-1	NNS	O
inhibitors	inhibitor	NNS	O
had	have	VBD	O
significant	significant	JJ	O
pharmacologic	pharmacologic	NN	O
effects	effect	NNS	O
,	,	,	O
including	include	VBG	O
decreased	decrease	VBN	O
TAG	TAG	NNP	O
,	,	,	O
which	which	WDT	O
were	be	VBD	O
consistent	consistent	JJ	O
with	with	IN	O
the	the	DT	O
DGAT1	DGAT1	NNP	O
knockout	knockout	NNP	O
mice	mouse	NNS	O
phenotypes	phenotype	VBZ	B
.	.	.	O

However	however	RB	O
,	,	,	O
DGAT2	DGAT2	VBZ	O
knockout	knockout	NN	O
mice	mouse	NNS	O
had	have	VBD	O
extremely	extremely	RB	O
low	low	JJ	O
levels	level	NNS	O
of	of	IN	O
TAG	TAG	NNP	O
,	,	,	O
and	and	CC	O
their	-PRON-	PRP$	O
skin	skin	NN	O
could	could	MD	O
not	not	RB	O
protect	protect	VB	O
against	against	IN	O
moisture	moisture	NN	O
,	,	,	O
so	so	IN	O
these	these	DT	O
mice	mouse	NNS	O
died	die	VBD	O
after	after	IN	O
birth	birth	NN	B
.	.	.	O

Therefore	therefore	RB	O
,	,	,	O
selective	selective	JJ	O
DGAT-1	DGAT-1	NNP	O
inhibitors	inhibitor	NNS	O
have	have	VBP	O
been	be	VBN	O
developed	develop	VBN	O
to	to	TO	O
manage	manage	VB	O
metabolic	metabolic	JJ	O
diseases	disease	NNS	O
such	such	JJ	O
as	as	IN	O
obesity	obesity	NN	O
and	and	CC	O
type	type	NN	O
2	2	CD	O
diabetes	diabetes	NN	B
.	.	.	O

Pharmaceutical	pharmaceutical	JJ	O
companies	company	NNS	O
,	,	,	O
including	include	VBG	O
AstraZeneca	AstraZeneca	NNP	B
,	,	,	O
Novartis	Novartis	NNP	B
,	,	,	O
Pfizer	Pfizer	NNP	B
,	,	,	O
and	and	CC	O
Abbott	Abbott	NNP	B
,	,	,	O
and	and	CC	O
Hoffmann	Hoffmann	NNP	O
-	-	HYPH	O
La	La	NNP	O
Roche	Roche	NNP	B
are	be	VBP	O
developing	develop	VBG	O
selective	selective	JJ	O
DGAT-1	DGAT-1	NNS	O
inhibitors	inhibitor	NNS	O
,	,	,	O
whose	whose	WP$	O
structures	structure	NNS	O
are	be	VBP	O
described	describe	VBN	O
in	in	IN	O
Figure	Figure	NNP	O
1	1	CD	O
.	.	.	O

Other	other	JJ	O
novel	novel	NN	O
DGAT1	DGAT1	NNP	O
inhibitors	inhibitor	NNS	O
have	have	VBP	O
also	also	RB	O
been	be	VBN	O
reported	report	VBN	B
.	.	.	O

Structures	structure	NNS	O
of	of	IN	O
reported	report	VBN	O
DGAT1	DGAT1	NNP	O
inhibitors	inhibitor	NNS	O
;	;	:	O
diagram	diagram	NNP	O
showing	show	VBG	O
structural	structural	JJ	O
features	feature	NNS	O
of	of	IN	O
DGAT-1	DGAT-1	NNS	O
inhibitors	inhibitor	NNS	O
.	.	.	O

Herein	Herein	NNP	O
,	,	,	O
we	-PRON-	PRP	O
described	describe	VBD	O
the	the	DT	O
discovery	discovery	NN	O
of	of	IN	O
novel	novel	JJ	O
thienopyrimidine	thienopyrimidine	NN	O
derivatives	derivative	NNS	O
as	as	IN	O
DGAT-1	DGAT-1	NNS	O
inhibitors	inhibitor	NNS	O
.	.	.	O

Target	target	NN	O
molecules	molecule	NNS	O
were	be	VBD	O
designed	design	VBN	O
based	base	VBN	O
on	on	IN	O
a	a	DT	O
bioisosteric	bioisosteric	JJ	O
replacement	replacement	NN	O
strategy	strategy	NN	O
.	.	.	O

Introduction	introduction	NN	O
of	of	IN	O
a	a	DT	O
heterobicylcle	heterobicylcle	NN	O
instead	instead	RB	O
of	of	IN	O
a	a	DT	O
phenyl	phenyl	NNP	O
linker	linker	NN	O
was	be	VBD	O
attempted	attempt	VBN	O
.	.	.	O

Thienopyrimidines	thienopyrimidine	NNS	O
showed	show	VBD	O
various	various	JJ	O
pharmacologic	pharmacologic	NN	O
activities	activity	NNS	O
as	as	IN	O
a	a	DT	O
privileged	privileged	JJ	O
scaffold	scaffold	JJ	B
,	,	,	O
and	and	CC	O
the	the	DT	O
introduction	introduction	NN	O
of	of	IN	O
thienopyrimidine	thienopyrimidine	NN	O
was	be	VBD	O
the	the	DT	O
first	first	JJ	O
approach	approach	NN	O
to	to	IN	O
designing	design	VBG	O
novel	novel	JJ	O
inhibitors	inhibitor	NNS	O
based	base	VBN	O
on	on	IN	O
the	the	DT	O
structural	structural	JJ	O
features	feature	NNS	O
of	of	IN	O
reported	reported	JJ	O
DGAT-1	DGAT-1	NNP	O
inhibitors	inhibitor	NNS	O
.	.	.	O

A	a	DT	O
schematic	schematic	JJ	O
strategy	strategy	NN	O
for	for	IN	O
the	the	DT	O
design	design	NN	O
of	of	IN	O
target	target	NN	O
molecules	molecule	NNS	O
.	.	.	O

All	all	DT	O
commercial	commercial	JJ	O
chemicals	chemical	NNS	O
and	and	CC	O
solvents	solvent	NNS	O
were	be	VBD	O
reagent	reagent	JJ	O
grade	grade	NN	O
and	and	CC	O
were	be	VBD	O
used	use	VBN	O
without	without	IN	O
further	further	JJ	O
purification	purification	NN	O
.	.	.	O

Completion	completion	NN	O
of	of	IN	O
the	the	DT	O
reactions	reaction	NNS	O
was	be	VBD	O
monitored	monitor	VBN	O
by	by	IN	O
analytical	analytical	JJ	O
thin	thin	JJ	O
layer	layer	NN	O
chromatography	chromatography	NN	O
using	use	VBG	O
precoated	precoate	VBN	O
glass	glass	NN	O
-	-	HYPH	O
backed	back	VBN	O
plates	plate	NNS	O
E	E	NNP	O
-	-	NNP	O
Merck	Merck	NNP	O
,	,	,	O
silica	silica	NN	O
gel	gel	VBD	O
60	60	CD	O
F254	F254	NNP	O
0.25âmm	0.25âmm	NNP	O
.	.	.	O

For	for	IN	O
normal	normal	JJ	O
pressure	pressure	NN	O
and	and	CC	O
flash	flash	NN	O
column	column	NN	O
chromatography	chromatography	NN	O
purifications	purification	NNS	O
,	,	,	O
Merck	Merck	NNP	O
silica	silica	NN	O
gel	gel	VBD	O
60	60	CD	O
size	size	NN	O
70â230	70â230	NNS	O
and	and	CC	O
230â400	230â400	CD	O
mesh	mesh	NN	O
,	,	,	O
respectively	respectively	RB	O
was	be	VBD	O
used	use	VBN	O
.	.	.	O

1H	1H	NNP	O
and	and	CC	O
13C	13C	NNP	O
NMR	NMR	NNP	O
spectra	spectra	NNP	O
were	be	VBD	O
recorded	record	VBN	O
with	with	IN	O
an	an	DT	O
Avance	Avance	NNP	O
DPX-300	DPX-300	NNP	O
NMR	NMR	NNP	O
spectrometer	spectrometer	NNP	O
and	and	CC	O
Jeol	Jeol	NNP	O
600âMHz	600âmhz	NN	O
spectrometer	spectrometer	NN	O
Jeol	Jeol	NNP	O
Resonance	Resonance	NNP	O
ECZ	ECZ	NNP	O
600âR	600âr	CD	O
,	,	,	O
USA	USA	NNP	O
.	.	.	O

All	all	PDT	O
the	the	DT	O
1H	1H	NNP	O
and	and	CC	O
CYTOWANIEC	CYTOWANIEC	NNP	O
NMR	NMR	NNP	O
spectra	spectra	NNP	O
were	be	VBD	O
recorded	record	VBN	O
in	in	IN	O
deuterated	deuterate	VBN	O
chloroform	chloroform	NN	O
with	with	IN	O
tetramethylsilane	tetramethylsilane	NN	O
as	as	IN	O
an	an	DT	O
internal	internal	JJ	O
standard	standard	NN	O
or	or	CC	O
deuterated	deuterated	JJ	O
dimethyl	dimethyl	NN	O
sulfoxide	sulfoxide	NN	O
-d6	-d6	NNP	O
as	as	IN	O
solvents	solvent	NNS	O
;	;	:	O
chemical	chemical	NN	O
shifts	shift	NNS	O
are	be	VBP	O
reported	report	VBN	O
in	in	IN	O
Î	Î	NNP	O
´	´	CD	O
values	value	NNS	O
relative	relative	JJ	O
to	to	IN	O
the	the	DT	O
residual	residual	JJ	O
solvent	solvent	NN	O
peak	peak	NN	O
.	.	.	O

Multiplicity	multiplicity	NN	O
was	be	VBD	O
indicated	indicate	VBN	O
as	as	IN	O
follows	follow	VBZ	O
:	:	:	O
s	s	LS	O
;	;	:	O
d	d	NNP	O
;	;	:	O
t	t	NN	O
;	;	:	O
m	m	NNP	O
;	;	:	O
dd	dd	NNP	O
;	;	:	O
brs	brs	NN	O
.	.	.	O

Mass	Mass	NNP	O
spectra	spectra	NNP	O
were	be	VBD	O
obtained	obtain	VBN	O
on	on	IN	O
Waters	Waters	NNP	O
Aquity	Aquity	NNP	O
UPLC	UPLC	NNP	O
/	/	SYM	O
QTOF	QTOF	NNP	O
.	.	.	O

HPLC	HPLC	NNP	O
was	be	VBD	O
used	use	VBN	O
Agilent	Agilent	NNP	O
,	,	,	O
1200	1200	CD	O
series	series	NN	O
using	use	VBG	O
capcellpak	capcellpak	NNP	O
MGII	MGII	NNP	O
4.6âÃâ150âmm	4.6âãâ150âmm	CD	O
,	,	,	O
5âÎ¼m	5âî¼m	LS	O
eluted	elute	VBD	O
with	with	IN	O
a	a	DT	O
30âmin	30âmin	NN	O
gradient	gradient	NN	O
from	from	IN	O
20â70	20â70	CD	O
%	%	NN	O
acetonitrile	acetonitrile	NN	O
in	in	IN	O
water	water	NN	O
.	.	.	O

A	a	DT	O
mixture	mixture	NN	O
of	of	IN	O
7-bromo-4-chlorothienopyrimidine	7-bromo-4-chlorothienopyrimidine	CD	O
6	6	CD	O
13âg	13âg	CD	O
,	,	,	O
52.10âmmol	52.10âmmol	CD	O
,	,	,	O
CY	CY	NNP	O
C37043	C37043	NNP	O
,	,	,	O
KindChem	KindChem	NNP	O
Corporation	Corporation	NNP	O
,	,	,	O
China	China	NNP	O
,	,	,	O
t	t	NN	O
-	-	HYPH	O
butyl	butyl	NNP	O
4âphenylcarbamate	4âphenylcarbamate	NNP	O
7	7	CD	O
20âg	20âg	CD	O
,	,	,	O
62.70âmmol	62.70âmmol	CD	O
,	,	,	O
tetrakispalladium	tetrakispalladium	NN	O
3.16âg	3.16âg	CD	O
,	,	,	O
2.73âmmol	2.73âmmol	CD	O
and	and	CC	O
sodium	sodium	NN	O
carbonate	carbonate	NN	O
8.28âg	8.28âg	CD	O
.	.	.	O

78.12âmmol	78.12âmmol	CD	O
were	be	VBD	O
added	add	VBN	O
to	to	IN	O
100âmL	100âml	CD	O
of	of	IN	O
1,4-dioxane	1,4-dioxane	NN	O
/	/	SYM	O
water	water	NN	O
,	,	,	O
and	and	CC	O
then	then	RB	O
stirred	stir	VBD	O
at	at	IN	O
80âÂ	80âÂ	NNP	O
°	°	NNP	O
C	C	NNP	O
for	for	IN	O
18âh	18âh	CD	O
under	under	IN	O
argon	argon	NN	O
atmosphere	atmosphere	NN	O
.	.	.	O

The	the	DT	O
organic	organic	JJ	O
layer	layer	NN	O
was	be	VBD	O
extracted	extract	VBN	O
with	with	IN	O
300âmL	300âml	CD	O
of	of	IN	O
ethyl	ethyl	NNP	O
acetate	acetate	NNP	O
and	and	CC	O
300âmL	300âml	CD	O
of	of	IN	O
water	water	NN	O
,	,	,	O
dried	dry	VBN	O
over	over	IN	O
anhydrous	anhydrous	JJ	O
magnesium	magnesium	NN	O
sulphate	sulphate	NN	O
,	,	,	O
and	and	CC	O
then	then	RB	O
concentrated	concentrate	VBD	O
in	in	IN	O
vacuo	vacuo	NNS	O
.	.	.	O

Subsequently	subsequently	RB	O
,	,	,	O
30âmL	30âml	CD	O
of	of	IN	O
methanol	methanol	NN	O
was	be	VBD	O
added	add	VBN	O
,	,	,	O
and	and	CC	O
the	the	DT	O
resulting	result	VBG	O
mixture	mixture	NN	O
was	be	VBD	O
stirred	stir	VBN	O
to	to	TO	O
precipitate	precipitate	VB	O
out	out	RP	O
solids	solid	NNS	O
,	,	,	O
and	and	CC	O
then	then	RB	O
filtered	filter	VBD	O
to	to	TO	O
obtain	obtain	VB	O
12.5âg	12.5âg	CD	O
of	of	IN	O
the	the	DT	O
yellow	yellow	JJ	O
title	title	NN	O
compound	compound	NN	O
.	.	.	O

A	a	DT	O
mixture	mixture	NN	O
of	of	IN	O
8	8	CD	O
0.56âg	0.56âg	CD	O
,	,	,	O
1.38âmmol	1.38âmmol	NNP	O
,	,	,	O
2â(4-cyclohex-3-en-1-yl)acetate	2â(4-cyclohex-3-en-1-yl)acetate	CD	O
9	9	CD	O
0.5âg	0.5âg	CD	O
,	,	,	O
1.78âmmol	1.78âmmol	NNP	O
,	,	,	O
which	which	WDT	O
was	be	VBD	O
prepared	prepare	VBN	O
according	accord	VBG	O
to	to	IN	O
the	the	DT	O
reported	report	VBN	O
method	method	NN	B
,	,	,	O
and	and	CC	O
tetrakispalladium	tetrakispalladium	NN	O
94.9âmg	94.9âmg	NNP	O
,	,	,	O
0.08âmmol	0.08âmmol	NNP	O
was	be	VBD	O
added	add	VBN	O
to	to	IN	O
a	a	DT	O
solution	solution	NN	O
of	of	IN	O
2.06âmL	2.06âml	CD	O
of	of	IN	O
2âN	2ân	CD	O
aqueous	aqueous	JJ	O
sodium	sodium	NN	O
carbonate	carbonate	NN	O
and	and	CC	O
8.2âmL	8.2âml	CD	O
of	of	IN	O
1,4-dioxane	1,4-dioxane	CD	O
,	,	,	O
and	and	CC	O
then	then	RB	O
stirred	stir	VBD	O
at	at	IN	O
100âÂ	100ââ	CD	O
°	°	,	O
C	C	NNP	O
for	for	IN	O
12âh	12âh	CD	O
under	under	IN	O
argon	argon	NN	O
.	.	.	O

The	the	DT	O
reaction	reaction	NN	O
mixture	mixture	NN	O
was	be	VBD	O
extracted	extract	VBN	O
with	with	IN	O
300âmL	300âml	CD	O
of	of	IN	O
ethyl	ethyl	NNP	O
acetate	acetate	NNP	O
and	and	CC	O
300âmL	300âml	CD	O
of	of	IN	O
water	water	NN	O
.	.	.	O

The	the	DT	O
organic	organic	JJ	O
layer	layer	NN	O
was	be	VBD	O
dried	dry	VBN	O
with	with	IN	O
anhydrous	anhydrous	JJ	O
magnesium	magnesium	NN	O
sulphate	sulphate	NN	O
,	,	,	O
filtered	filter	VBN	O
and	and	CC	O
then	then	RB	O
concentrated	concentrate	VBD	O
.	.	.	O

Subsequently	subsequently	RB	O
,	,	,	O
methanol	methanol	NN	O
was	be	VBD	O
added	add	VBN	O
to	to	IN	O
the	the	DT	O
resulting	result	VBG	O
solution	solution	NN	O
,	,	,	O
stirred	stir	VBN	O
to	to	TO	O
precipitate	precipitate	VB	O
out	out	RP	O
solids	solid	NNS	O
,	,	,	O
and	and	CC	O
then	then	RB	O
filtered	filter	VBD	O
to	to	TO	O
obtain	obtain	VB	O
315âmg	315âmg	CD	O
of	of	IN	O
the	the	DT	O
yellow	yellow	JJ	O
title	title	NN	O
compound	compound	NN	O
.	.	.	O

To	to	IN	O
a	a	DT	O
solution	solution	NN	O
of	of	IN	O
10	10	CD	O
315âmg	315âmg	CD	O
,	,	,	O
0.66âmmol	0.66âmmol	NNP	O
in	in	IN	O
ethanol	ethanol	NN	O
50âmL	50âml	NN	O
and	and	CC	O
1,4-dioxane	1,4-dioxane	NN	O
20âmL	20âml	CD	O
was	be	VBD	O
added	add	VBN	O
20	20	CD	O
%	%	NN	O
charcoal	charcoal	NN	O
-	-	HYPH	O
shaped	shape	VBN	O
palladium	palladium	NN	O
hydroxide	hydroxide	NN	O
158âmg	158âmg	CD	O
,	,	,	O
50%w	50%w	CD	O
/	/	SYM	O
w	w	NN	O
.	.	.	O

The	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
stirred	stir	VBN	O
at	at	IN	O
room	room	NN	O
temperature	temperature	NN	O
under	under	IN	O
H2	H2	NNP	O
overnight	overnight	RB	O
.	.	.	O

The	the	DT	O
reaction	reaction	NN	O
mixture	mixture	NN	O
was	be	VBD	O
filtered	filter	VBN	O
through	through	IN	O
Celite	Celite	NNP	O
,	,	,	O
and	and	CC	O
then	then	RB	O
the	the	DT	O
filtrate	filtrate	NN	O
was	be	VBD	O
concentrated	concentrated	JJ	O
to	to	TO	O
obtain	obtain	VB	O
the	the	DT	O
title	title	NN	O
compound	compound	NN	O
11	11	CD	O
190âmg	190âmg	CD	O
,	,	,	O
which	which	WDT	O
was	be	VBD	O
used	use	VBN	O
in	in	IN	O
the	the	DT	O
following	follow	VBG	O
step	step	NN	O
without	without	IN	O
further	further	JJ	O
purification	purification	NN	O
.	.	.	O

To	to	IN	O
a	a	DT	O
solution	solution	NN	O
of	of	IN	O
11	11	CD	O
280âmg	280âmg	CD	O
,	,	,	O
0.58âmmol	0.58âmmol	NNP	O
in	in	IN	O
dichloromethane	dichloromethane	NNP	O
5âmL	5âml	NN	O
was	be	VBD	O
added	add	VBN	O
0.6âmL	0.6âmL	NNP	O
of	of	IN	O
trifluoroacetic	trifluoroacetic	JJ	O
acid	acid	NN	O
.	.	.	O

The	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
stirred	stir	VBN	O
at	at	IN	O
room	room	NN	O
temperature	temperature	NN	O
for	for	IN	O
12âh	12âh	CD	O
.	.	.	O

Then	then	RB	O
the	the	DT	O
reaction	reaction	NN	O
mixture	mixture	NN	O
was	be	VBD	O
concentrated	concentrate	VBN	O
to	to	IN	O
a	a	DT	O
residue	residue	NN	O
that	that	WDT	O
was	be	VBD	O
partitioned	partition	VBN	O
between	between	IN	O
dichloromethane	dichloromethane	NNP	O
and	and	CC	O
saturated	saturate	VBD	O
aqueous	aqueous	JJ	O
sodium	sodium	NN	O
bicarbonate	bicarbonate	NN	O
.	.	.	O

The	the	DT	O
organic	organic	JJ	O
layer	layer	NN	O
was	be	VBD	O
separated	separate	VBN	O
from	from	IN	O
the	the	DT	O
aqueous	aqueous	JJ	O
layer	layer	NN	O
,	,	,	O
washed	wash	VBN	O
with	with	IN	O
brine	brine	NN	O
,	,	,	O
dried	dry	VBN	O
over	over	IN	O
anhydrous	anhydrous	JJ	O
magnesium	magnesium	NN	O
sulphate	sulphate	NN	O
,	,	,	O
and	and	CC	O
then	then	RB	O
concentrated	concentrate	VBD	O
to	to	TO	O
afford	afford	VB	O
190âmg	190âmg	CD	O
of	of	IN	O
the	the	DT	O
title	title	NN	O
compound	compound	NN	O
.	.	.	O

To	to	IN	O
a	a	DT	O
solution	solution	NN	O
of	of	IN	O
12	12	CD	O
3.1âg	3.1âg	CD	O
,	,	,	O
8.13âmmol	8.13âmmol	NNP	O
in	in	IN	O
anhydrous	anhydrous	JJ	O
tetrahydrofuran	tetrahydrofuran	NN	O
60âmL	60âmL	NNP	O
was	be	VBD	O
added	add	VBN	O
3-chlorophenyl	3-chlorophenyl	CD	O
isocyanate	isocyanate	NN	O
1.37âg	1.37âg	CD	O
,	,	,	O
8.92âmmol	8.92âmmol	CD	O
.	.	.	O

The	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
stirred	stir	VBN	O
at	at	IN	O
room	room	NN	O
temperature	temperature	NN	O
for	for	IN	O
18âh	18âh	CD	O
.	.	.	O

The	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
concentrated	concentrate	VBN	O
in	in	IN	O
part	part	NN	O
and	and	CC	O
diluted	dilute	VBN	O
with	with	IN	O
diethyl	diethyl	NN	O
ether	ether	NN	O
to	to	TO	O
give	give	VB	O
a	a	DT	O
precipitate	precipitate	NN	O
,	,	,	O
which	which	WDT	O
was	be	VBD	O
filtered	filter	VBN	O
to	to	TO	O
afford	afford	VB	O
4.06âg	4.06âg	CD	O
of	of	IN	O
a	a	DT	O
light	light	JJ	O
-	-	HYPH	O
yellow	yellow	JJ	O
title	title	NN	O
compound.13	compound.13	NNP	O
150âmg	150âmg	CD	O
,	,	,	O
0.28âmmol	0.28âmmol	NNP	O
was	be	VBD	O
added	add	VBN	O
to	to	IN	O
ethyl	ethyl	NNP	O
acetate	acetate	NNP	O
2âmL	2âml	CD	O
and	and	CC	O
stirred	stir	VBN	O
at	at	IN	O
70âÂ	70âÂ	NNP	O
°	°	,	O
C	C	NNP	O
for	for	IN	O
12âh	12âh	CD	O
,	,	,	O
and	and	CC	O
then	then	RB	O
cooled	cool	VBD	O
to	to	TO	O
room	room	VB	O
temperature	temperature	NN	O
to	to	TO	O
give	give	VB	O
a	a	DT	O
solid	solid	JJ	O
.	.	.	O

The	the	DT	O
solid	solid	JJ	O
15b	15b	NNS	O
,	,	,	O
72âmg	72âmg	CD	O
was	be	VBD	O
filtered	filter	VBN	O
,	,	,	O
and	and	CC	O
then	then	RB	O
the	the	DT	O
filtrate	filtrate	NN	O
was	be	VBD	O
concentrated	concentrate	VBN	O
and	and	CC	O
the	the	DT	O
residue	residue	NN	O
was	be	VBD	O
purified	purify	VBN	O
by	by	IN	O
silica	silica	NNP	O
gel	gel	NN	O
column	column	NN	O
chromatography	chromatography	NN	O
to	to	TO	O
give	give	VB	O
76âmg	76âmg	CD	O
of	of	IN	O
the	the	DT	O
yellow	yellow	JJ	O
title	title	NN	O
compound	compound	NNP	O
15a	15a	NNS	O
.	.	.	O

To	to	IN	O
a	a	DT	O
solution	solution	NN	O
of	of	IN	O
15a	15a	NNS	O
7.8âg	7.8âg	CD	O
,	,	,	O
14.58âmmol	14.58âmmol	CD	O
in	in	IN	O
tetrahydrofuran	tetrahydrofuran	NN	O
/	/	SYM	O
methanol	methanol	NN	O
/	/	SYM	O
water	water	NN	O
120âmL	120âml	CD	O
,	,	,	O
1:1:1	1:1:1	CD	O
was	be	VBD	O
added	add	VBN	O
1.17âg	1.17âg	CD	O
of	of	IN	O
sodium	sodium	NN	O
hydroxide	hydroxide	NN	O
29.25âmmol	29.25âmmol	CD	O
,	,	,	O
and	and	CC	O
the	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
stirred	stir	VBN	O
.	.	.	O

The	the	DT	O
reaction	reaction	NN	O
mixture	mixture	NN	O
was	be	VBD	O
acidified	acidify	VBN	O
with	with	IN	O
1âN	1âN	NNS	O
HCl	HCl	NNS	O
to	to	TO	O
give	give	VB	O
a	a	DT	O
solid	solid	JJ	O
.	.	.	O

The	the	DT	O
solid	solid	JJ	O
was	be	VBD	O
filtered	filter	VBN	O
,	,	,	O
and	and	CC	O
washed	wash	VBN	O
with	with	IN	O
water	water	NN	O
to	to	TO	O
afford	afford	VB	O
16a	16a	NNS	O
quantitatively	quantitatively	RB	O
.	.	.	O

To	to	IN	O
a	a	DT	O
solution	solution	NN	O
of	of	IN	O
16a	16a	NNS	O
7.6âg	7.6âg	CD	O
,	,	,	O
14.59âmmol	14.59âmmol	CD	O
in	in	IN	O
100âmL	100âml	CD	O
of	of	IN	O
methanol	methanol	NN	O
was	be	VBD	O
added	add	VBN	O
14âmL	14âml	CD	O
of	of	IN	O
a	a	DT	O
1âN	1ân	JJ	O
sodium	sodium	NN	O
hydroxide	hydroxide	NN	O
.	.	.	O

The	the	DT	O
resulting	result	VBG	O
mixture	mixture	NN	O
was	be	VBD	O
stirred	stir	VBN	O
at	at	IN	O
room	room	NN	O
temperature	temperature	NN	O
for	for	IN	O
2âh	2âh	CD	O
.	.	.	O

The	the	DT	O
solvent	solvent	NN	O
was	be	VBD	O
removed	remove	VBN	O
to	to	TO	O
give	give	VB	O
8.3âg	8.3âg	CD	O
of	of	IN	O
the	the	DT	O
yellow	yellow	JJ	O
title	title	NN	O
compound	compound	NN	O
17a	17a	NNS	O
.	.	.	O

The	the	DT	O
activity	activity	NN	O
of	of	IN	O
DGAT-1	DGAT-1	NNP	O
inhibitors	inhibitor	NNS	O
inÂ	inÂ	NNP	O
vitro	vitro	FW	O
was	be	VBD	O
evaluated	evaluate	VBN	O
by	by	IN	O
using	use	VBG	O
a	a	DT	O
human	human	JJ	O
recombinant	recombinant	JJ	O
DGAT1	DGAT1	NNP	O
enzyme	enzyme	NNS	O
expressed	express	VBD	O
in	in	IN	O
insect	insect	JJ	O
cells	cell	NNS	O
.	.	.	O

SF9	sf9	JJ	O
cells	cell	NNS	O
were	be	VBD	O
homogenised	homogenise	VBN	O
by	by	IN	O
washing	wash	VBG	O
them	-PRON-	PRP	O
with	with	IN	O
DPBS	DPBS	NNP	O
Dulbeccoâs	dulbeccoâs	CD	O
phosphate	phosphate	RB	O
-	-	HYPH	O
buffered	buffered	JJ	O
saline	saline	NN	O
and	and	CC	O
then	then	RB	O
suspending	suspend	VBG	O
cell	cell	NN	O
pellets	pellet	NNS	O
with	with	IN	O
a	a	DT	O
tris	tris	NNP	O
buffer	buffer	NN	O
250âmM	250âmm	CD	O
sucrose	sucrose	JJ	O
;	;	:	O
10âmM	10âmm	CD	O
Tris	Tris	NNP	O
-	-	HYPH	O
HCl	HCl	NNP	O
;	;	:	O
proteinase	proteinase	NN	O
inhibitor	inhibitor	NN	O
.	.	.	O

The	the	DT	O
resulting	result	VBG	O
mixture	mixture	NN	O
was	be	VBD	O
centrifugally	centrifugally	RB	O
separated	separate	VBN	O
at	at	IN	O
10,000	10,000	CD	O
Ã	ã	IN	O
g	g	NNP	O
for	for	IN	O
30âmin	30âmin	NNP	O
to	to	TO	O
remove	remove	VB	O
the	the	DT	O
cell	cell	NN	O
debris	debris	NN	O
remaining	remain	VBG	O
in	in	IN	O
the	the	DT	O
lower	low	JJR	O
layer	layer	NN	O
thereof	thereof	RB	O
,	,	,	O
and	and	CC	O
was	be	VBD	O
centrifugally	centrifugally	RB	O
separated	separate	VBN	O
at	at	IN	O
100,000	100,000	CD	O
Ã	ã	IN	O
g	g	NN	O
for	for	IN	O
60âmin	60âmin	NNP	O
to	to	TO	O
obtain	obtain	VB	O
a	a	DT	O
microsomal	microsomal	JJ	O
membrane	membrane	NN	O
.	.	.	O

Further	further	RB	O
,	,	,	O
membrane	membrane	NN	O
fractions	fraction	NNS	O
were	be	VBD	O
resuspended	resuspend	VBN	O
by	by	IN	O
the	the	DT	O
tris	tris	NNP	O
buffer	buffer	NNP	O
,	,	,	O
and	and	CC	O
then	then	RB	O
stored	store	VBD	O
at	at	IN	O
-80âÂ	-80âÂ	NNP	O
°	°	,	O
C	C	NNP	O
.	.	.	O

The	the	DT	O
activity	activity	NN	O
of	of	IN	O
DGAT1	DGAT1	NNP	O
was	be	VBD	O
measured	measure	VBN	O
according	accord	VBG	O
to	to	IN	O
the	the	DT	O
reported	report	VBN	O
method	method	NN	B
.	.	.	O

Specifically	specifically	RB	O
,	,	,	O
0.0001	0.0001	CD	O
â	â	NN	O
10	10	CD	O
Î¼Î	Î¼Î	NNS	O
of	of	IN	O
the	the	DT	O
test	test	NN	O
compounds	compound	NNS	O
were	be	VBD	O
cultured	culture	VBN	O
at	at	IN	O
room	room	NN	O
temperature	temperature	NN	O
25âÂ	25ââ	CD	O
°	°	,	O
C	C	NNP	O
for	for	IN	O
15âmin	15âmin	CD	O
with	with	IN	O
a	a	DT	O
10	10	CD	O
Î¼Î	Î¼Î	NNS	O
of	of	IN	O
SF9	SF9	NNP	O
microsomal	microsomal	JJ	O
protein	protein	NN	O
solution	solution	NN	O
and	and	CC	O
100âmM	100âmm	CD	O
of	of	IN	O
MgCl2	MgCl2	NNP	O
solution	solution	NN	O
,	,	,	O
and	and	CC	O
were	be	VBD	O
then	then	RB	O
further	further	RB	O
cultured	culture	VBN	O
at	at	IN	O
room	room	NN	O
temperature	temperature	NN	O
25âÂ	25ââ	CD	O
°	°	,	O
C	C	NNP	O
for	for	IN	O
30âmin	30âmin	NN	O
after	after	IN	O
the	the	DT	O
addition	addition	NN	O
of	of	IN	O
100	100	CD	O
Î¼Î	Î¼Î	NNP	O
of	of	IN	O
1,2-dioleyl	1,2-dioleyl	NNP	O
-	-	HYPH	O
sn	sn	NNP	O
-	-	HYPH	O
glycerol	glycerol	NNP	O
and	and	CC	O
30	30	CD	O
Î¼Î	Î¼Î	,	O
of	of	IN	O
CYTOWANIEC	CYTOWANIEC	NNP	O
-	-	HYPH	O
oleyl	oleyl	NNP	O
coenzyme	coenzyme	NNS	O
A.	A.	NNP	O
The	the	DT	O
reaction	reaction	NN	O
was	be	VBD	O
completed	complete	VBN	O
by	by	IN	O
the	the	DT	O
addition	addition	NN	O
of	of	IN	O
300âÎ¼L	300âî¼l	CD	O
of	of	IN	O
a	a	DT	O
mixed	mixed	JJ	O
solution	solution	NN	O
of	of	IN	O
2-propanol	2-propanol	CD	O
/	/	SYM	O
heptane	heptane	NN	O
,	,	,	O
and	and	CC	O
radioactive	radioactive	JJ	O
triglyceride	triglyceride	NN	O
was	be	VBD	O
separated	separate	VBN	O
from	from	IN	O
an	an	DT	O
organic	organic	JJ	O
solvent	solvent	NN	O
layer	layer	NN	O
by	by	IN	O
using	use	VBG	O
200âÎ¼L	200âî¼l	CD	O
of	of	IN	O
heptane	heptane	NN	O
and	and	CC	O
200âÎ¼L	200âî¼l	CD	O
of	of	IN	O
a	a	DT	O
0.1âM	0.1âm	CD	O
carbonate	carbonate	NN	O
buffer	buffer	NN	O
.	.	.	O

The	the	DT	O
amount	amount	NN	O
of	of	IN	O
triglyceride	triglyceride	NN	O
was	be	VBD	O
measured	measure	VBN	O
by	by	IN	O
liquid	liquid	JJ	O
scintillography	scintillography	NN	O
after	after	IN	O
mixing	mix	VBG	O
with	with	IN	O
an	an	DT	O
organic	organic	JJ	O
solvent	solvent	NN	O
and	and	CC	O
an	an	DT	O
equivalent	equivalent	JJ	O
amount	amount	NN	O
of	of	IN	O
scintillation	scintillation	NN	O
solvent	solvent	NN	O
.	.	.	O

The	the	DT	O
effects	effect	NNS	O
of	of	IN	O
inhibiting	inhibit	VBG	O
DGAT1	DGAT1	NNS	O
were	be	VBD	O
calculated	calculate	VBN	O
as	as	IN	O
percent	percent	NN	O
in	in	IN	O
comparison	comparison	NN	O
with	with	IN	O
a	a	DT	O
control	control	NN	O
material	material	NN	O
.	.	.	O

Male	Male	NNP	O
,	,	,	O
Institute	Institute	NNP	O
of	of	IN	O
Cancer	Cancer	NNP	O
Research	Research	NNP	O
mice	mouse	NNS	O
were	be	VBD	O
obtained	obtain	VBN	O
from	from	IN	O
OrientBio	OrientBio	NNP	O
Inc.	Inc.	NNP	O
.	.	.	O

ICR	ICR	NNP	O
mice	mouse	NNS	O
8-weeks	8-weeks	CD	O
old	old	JJ	O
,	,	,	O
nâ=â5	nâ=â5	NNP	O
/	/	SYM	O
group	group	NN	O
fasted	fast	VBD	O
16âh	16âh	CD	O
,	,	,	O
received	receive	VBD	O
5âmL	5âml	CD	O
/	/	SYM	O
kg	kg	NN	O
corn	corn	NN	O
oil	oil	NN	O
via	via	IN	O
oral	oral	JJ	O
administration	administration	NN	O
30âmin	30âmin	NNP	O
after	after	IN	O
compound	compound	NNP	O
administration	administration	NN	O
.	.	.	O

Plasma	Plasma	NNP	O
was	be	VBD	O
collected	collect	VBN	O
at	at	IN	O
different	different	JJ	O
time	time	NN	O
points	point	NNS	O
0	0	CD	O
,	,	,	O
1	1	CD	O
,	,	,	O
2	2	CD	O
,	,	,	O
and	and	CC	O
4âh	4âh	CD	O
.	.	.	O

Beagle	Beagle	NNP	O
dogs	dog	NNS	O
9âmonths	9âmonths	CD	O
old	old	JJ	O
,	,	,	O
nâ=â2	nâ=â2	NNP	O
/	/	SYM	O
group	group	NN	O
were	be	VBD	O
obtained	obtain	VBN	O
from	from	IN	O
Woojung	Woojung	NNP	O
Bio	Bio	NNP	O
Inc.	Inc.	NNP	O
were	be	VBD	O
fasted	fast	VBN	O
for	for	IN	O
16âh	16âh	CD	O
and	and	CC	O
received	receive	VBD	O
heavy	heavy	JJ	O
cream	cream	NN	O
2.7âmL	2.7âmL	NNP	O
/	/	SYM	O
kg	kg	NNP	O
,	,	,	O
glucose	glucose	NNP	O
1âg	1âg	CD	O
/	/	SYM	O
kg	kg	NNP	O
,	,	,	O
water	water	NN	O
5.3âmL	5.3âmL	NNP	O
/	/	SYM	O
kg	kg	NNP	O
,	,	,	O
and	and	CC	O
acetaminophen	acetaminophen	NNP	O
20âmg	20âmg	NNP	O
/	/	SYM	O
kg	kg	NNP	O
p.o	p.o	NNP	O
.	.	NNP	O

1âh	1âh	CD	O
after	after	IN	O
compound	compound	NNP	O
administration	administration	NN	O
.	.	.	O

Blood	blood	NN	O
samples	sample	NNS	O
were	be	VBD	O
collected	collect	VBN	O
at	at	IN	O
â0.5	â0.5	NNP	O
,	,	,	O
0	0	CD	O
,	,	,	O
1	1	CD	O
,	,	,	O
2	2	CD	O
,	,	,	O
and	and	CC	O
4âh	4âh	CD	O
.	.	.	O

Statistical	statistical	JJ	O
analysis	analysis	NN	O
was	be	VBD	O
performed	perform	VBN	O
using	use	VBG	O
one	one	CD	O
-	-	HYPH	O
way	way	NN	O
ANOVA	ANOVA	NNP	O
,	,	,	O
followed	follow	VBN	O
by	by	IN	O
Dunnettâs	dunnettâs	CD	O
multiple	multiple	JJ	O
comparison	comparison	NN	O
test	test	NN	O
using	use	VBG	O
Prism	Prism	NNP	O
6.0	6.0	CD	O
.	.	.	O

The	the	DT	O
Kruskal	Kruskal	NNP	O
-	-	HYPH	O
Wallis	Wallis	NNP	O
test	test	NN	O
was	be	VBD	O
applied	apply	VBN	O
when	when	WRB	O
data	datum	NNS	O
did	do	VBD	O
not	not	RB	O
pass	pass	VB	O
the	the	DT	O
normality	normality	NN	O
test	test	NN	O
.	.	.	O

We	-PRON-	PRP	O
found	find	VBD	O
that	that	IN	O
thienopyrimidine	thienopyrimidine	NN	O
could	could	MD	O
be	be	VB	O
a	a	DT	O
core	core	NN	O
scaffold	scaffold	NN	O
connecting	connect	VBG	O
an	an	DT	O
aryl	aryl	NNP	O
moiety	moiety	NN	O
at	at	IN	O
one	one	CD	O
end	end	NN	O
to	to	IN	O
a	a	DT	O
cyclo	cyclo	NN	O
-	-	HYPH	O
aliphatic	aliphatic	JJ	O
carboxylic	carboxylic	JJ	O
acid	acid	NN	O
group	group	NN	O
at	at	IN	O
the	the	DT	O
other	other	JJ	O
.	.	.	O

Synthetic	synthetic	JJ	O
schemes	scheme	NNS	O
for	for	IN	O
a	a	DT	O
series	series	NN	O
of	of	IN	O
thienopyrimidine	thienopyrimidine	NN	O
derivatives	derivative	NNS	O
are	be	VBP	O
outlined	outline	VBN	O
in	in	IN	O
Schemes	Schemes	NNP	O
1	1	CD	O
and	and	CC	O
2	2	CD	O
.	.	.	O

Desired	desire	VBN	O
compounds	compound	NNS	O
14aâ14l	14aâ14l	NNP	O
were	be	VBD	O
synthesised	synthesise	VBN	O
from	from	IN	O
commercially	commercially	RB	O
available	available	JJ	O
7-bromo-4-chlorothienopyrimidine	7-bromo-4-chlorothienopyrimidine	CD	O
,	,	,	O
as	as	IN	O
shown	show	VBN	O
in	in	IN	O
Scheme	Scheme	NNP	O
1	1	CD	O
.	.	.	O

Consecutive	Consecutive	NNP	O
Suzuki	Suzuki	NNP	O
coupling	couple	VBG	O
reactions	reaction	NNS	O
gave	give	VBD	O
8	8	CD	O
and	and	CC	O
10	10	CD	O
.	.	.	O

Compound	Compound	NNP	O
9	9	CD	O
was	be	VBD	O
prepared	prepare	VBN	O
using	use	VBG	O
the	the	DT	O
reported	report	VBN	O
method	method	NN	B
.	.	.	O

Hydrogenation	Hydrogenation	NNP	O
of	of	IN	O
10	10	CD	O
,	,	,	O
followed	follow	VBN	O
by	by	IN	O
de	de	NN	O
-	-	NN	O
protection	protection	NN	O
of	of	IN	O
the	the	DT	O
Boc	Boc	NNP	O
group	group	NN	O
with	with	IN	O
trifluoroacetic	trifluoroacetic	JJ	O
acid	acid	NN	O
afforded	afford	VBD	O
the	the	DT	O
key	key	NN	O
intermediate	intermediate	JJ	O
12	12	CD	O
.	.	.	O

The	the	DT	O
aniline	aniline	NN	O
12	12	CD	O
was	be	VBD	O
converted	convert	VBN	O
to	to	IN	O
amides	amide	NNS	O
14aâ14h	14aâ14h	NNP	O
or	or	CC	O
ureas	urea	NNS	O
14iâ14l	14iâ14l	CD	O
by	by	IN	O
coupling	couple	VBG	O
with	with	IN	O
acid	acid	JJ	O
chlorides	chloride	NNS	O
or	or	CC	O
aryl	aryl	NNP	O
isocyanates	isocyanate	NNS	O
,	,	,	O
respectively	respectively	RB	O
,	,	,	O
followed	follow	VBN	O
by	by	IN	O
hydrolysis	hydrolysis	NN	O
with	with	IN	O
sodium	sodium	NN	O
hydroxide	hydroxide	NN	O
or	or	CC	O
lithium	lithium	NN	O
hydroxide	hydroxide	NN	O
.	.	.	O

Synthesis	synthesis	NN	O
of	of	IN	O
thienopyrimidine	thienopyrimidine	NN	O
derivatives	derivative	NNS	O
.	.	.	O

Reagents	reagent	NNS	O
and	and	CC	O
conditions	condition	NNS	O
:	:	:	O
Pd4	Pd4	NNP	O
,	,	,	O
2âN	2ân	CD	O
Na2CO3	Na2CO3	NNP	O
,	,	,	O
1,4-Dioxane	1,4-dioxane	CD	O
;	;	:	O
H2	H2	NNP	O
,	,	,	O
20	20	CD	O
%	%	NN	O
PdOH	pdoh	NN	O
,	,	,	O
EtOH/1,4-Dioxane	EtOH/1,4-Dioxane	NNP	O
;	;	:	O
TFA	TFA	NNP	O
,	,	,	O
DCM	DCM	NNP	O
,	,	,	O
rt	rt	NNP	O
;	;	:	O
aryl	aryl	NNP	O
chloride	chloride	NNP	O
,	,	,	O
pyridine	pyridine	NNP	O
,	,	,	O
DCM	DCM	NNP	O
0âÂ	0ââ	CD	O
°	°	,	O
C	C	NNP	O
to	to	IN	O
rt	rt	NNP	O
or	or	CC	O
aryl	aryl	NNP	O
isocyanate	isocyanate	VBP	O
,	,	,	O
THF	THF	NNP	O
,	,	,	O
12âh	12âh	CD	O
,	,	,	O
rt	rt	NNP	O
;	;	:	O
NaOH	NaOH	NNP	O
or	or	CC	O
LiOH	LiOH	NNP	O
,	,	,	O
THF	THF	NNP	O
/	/	SYM	O
MeOH	MeOH	NNP	O
/	/	SYM	O
H2O	H2O	NNP	O
,	,	,	O
rt	rt	NNP	O
.	.	.	O

The	the	DT	O
activities	activity	NNS	O
of	of	IN	O
synthesised	synthesise	VBN	O
compounds	compound	NNS	O
were	be	VBD	O
evaluated	evaluate	VBN	O
using	use	VBG	O
SF9	SF9	NNP	O
insect	insect	NN	O
cells	cell	NNS	O
expressing	express	VBG	O
human	human	JJ	O
DGAT-1	DGAT-1	NNS	B
.	.	.	O

The	the	DT	O
IC50	IC50	NNP	O
values	value	NNS	O
are	be	VBP	O
summarised	summarise	VBN	O
in	in	IN	O
Table	table	NN	O
1	1	CD	O
.	.	.	O

A	a	DT	O
potent	potent	JJ	O
DGAT-1	DGAT-1	NNS	O
inhibitor	inhibitor	NN	O
,	,	,	O
LCQ-908	LCQ-908	NNP	O
was	be	VBD	O
used	use	VBN	O
as	as	IN	O
a	a	DT	O
positive	positive	JJ	O
control	control	NN	O
.	.	.	O

To	to	TO	O
optimise	optimise	VB	O
the	the	DT	O
alkyl	alkyl	NN	O
chain	chain	NN	O
length	length	NN	O
of	of	IN	O
the	the	DT	O
acid	acid	NN	O
moiety	moiety	NN	O
,	,	,	O
compound	compound	NN	O
14b	14b	NNS	O
nâ=â1	nâ=â1	NNP	O
was	be	VBD	O
more	more	RBR	O
potent	potent	JJ	O
than	than	IN	O
short	short	JJ	O
chain	chain	NN	O
14a	14a	NNS	O
nâ=â0	nâ=â0	NNP	O
and	and	CC	O
long	long	JJ	O
chain	chain	NN	O
14c	14c	NNS	O
nâ=â2	nâ=â2	NNP	O
.	.	.	O

The	the	DT	O
calculated	calculated	JJ	O
lowest	low	JJS	O
energy	energy	NN	O
conformation	conformation	NN	O
model	model	NN	O
of	of	IN	O
14c	14c	NNS	O
provided	provide	VBD	O
that	that	IN	O
the	the	DT	O
distance	distance	NN	O
between	between	IN	O
the	the	DT	O
terminal	terminal	JJ	O
carboxylic	carboxylic	JJ	O
acid	acid	NN	O
and	and	CC	O
NH	NH	NNP	O
of	of	IN	O
urea	urea	NNP	O
was	be	VBD	O
over	over	IN	O
16âÃ	16âÃ	NNP	O
		_SP	O
,	,	,	O
which	which	WDT	O
may	may	MD	O
result	result	VB	O
in	in	IN	O
reduced	reduced	JJ	O
activity	activity	NN	O
.	.	.	O

14a	14a	NNS	O
exhibited	exhibit	VBD	O
a	a	DT	O
loss	loss	NN	O
of	of	IN	O
activity	activity	NN	O
,	,	,	O
which	which	WDT	O
suggested	suggest	VBD	O
that	that	IN	O
the	the	DT	O
terminal	terminal	JJ	O
carboxylic	carboxylic	JJ	O
acid	acid	NN	O
should	should	MD	O
be	be	VB	O
placed	place	VBN	O
one	one	CD	O
-	-	HYPH	O
carbon	carbon	NN	O
away	away	RB	O
from	from	IN	O
cyclohexane	cyclohexane	NN	O
.	.	.	O

Next	next	RB	O
,	,	,	O
structure	structure	NN	O
-	-	HYPH	O
activity	activity	NN	O
relationships	relationship	NNS	O
for	for	IN	O
the	the	DT	O
aryl	aryl	NNP	O
moiety	moiety	NN	O
on	on	IN	O
the	the	DT	O
left	left	JJ	O
side	side	NN	O
were	be	VBD	O
investigated	investigate	VBN	O
,	,	,	O
with	with	IN	O
derivatives	derivative	NNS	O
bearing	bear	VBG	O
chain	chain	NN	O
lengths	length	VBZ	O
the	the	DT	O
same	same	JJ	O
as	as	IN	O
that	that	DT	O
of	of	IN	O
14b	14b	NNS	O
.	.	.	O

5-chloro-2-nitro	5-chloro-2-nitro	NNP	O
phenyl	phenyl	NNP	O
,	,	,	O
2-trifluoromethylpyridinyl	2-trifluoromethylpyridinyl	CD	O
,	,	,	O
4-chloropyridinyl	4-chloropyridinyl	CD	O
,	,	,	O
and	and	CC	O
5-bromopyridinyl	5-bromopyridinyl	CD	O
derivatives	derivative	NNS	O
had	have	VBD	O
no	no	DT	O
activity	activity	NN	O
IC50	IC50	NNP	O
>	>	XX	O
1âÎ¼M	1âî¼m	CD	O
,	,	,	O
while	while	IN	O
14b	14b	NNS	O
,	,	,	O
14c	14c	NNS	O
,	,	,	O
14e	14e	NNS	O
,	,	,	O
14h	14h	NNS	O
,	,	,	O
and	and	CC	O
14j	14j	NNS	O
had	have	VBD	O
good	good	JJ	O
activity	activity	NN	O
IC50	IC50	NNP	O
values	value	NNS	O
of	of	IN	O
0.3âÎ¼Mâ0.4âÎ¼M	0.3âî¼mâ0.4âî¼m	CD	O
.	.	.	O

Compounds	compound	NNS	O
14	14	CD	O
g	g	NN	O
and	and	CC	O
14i	14i	NNS	O
were	be	VBD	O
equipotent	equipotent	JJ	O
to	to	IN	O
the	the	DT	O
known	know	VBN	O
compound	compound	NN	O
2	2	CD	O
.	.	.	O

The	the	DT	O
most	most	RBS	O
potent	potent	JJ	O
compound	compound	NN	O
,	,	,	O
14i	14i	NNS	O
,	,	,	O
was	be	VBD	O
subjected	subject	VBN	O
to	to	IN	O
further	further	JJ	O
investigation	investigation	NN	O
.	.	.	O

Cis	Cis	NNP	O
and	and	CC	O
trans	trans	NNP	O
isomers	isomer	NNS	O
of	of	IN	O
14i	14i	CD	O
were	be	VBD	O
separated	separate	VBN	O
to	to	TO	O
determine	determine	VB	O
the	the	DT	O
activity	activity	NN	O
and	and	CC	O
properties	property	NNS	O
of	of	IN	O
each	each	DT	O
isomer	isomer	NN	O
.	.	.	O

As	as	IN	O
shown	show	VBN	O
in	in	IN	O
Scheme	Scheme	NNP	O
2	2	CD	O
,	,	,	O
the	the	DT	O
racemic	racemic	JJ	O
mixture	mixture	NN	O
13	13	CD	O
was	be	VBD	O
conveniently	conveniently	RB	O
separated	separate	VBN	O
into	into	IN	O
cis	cis	NN	O
-	-	HYPH	O
isomer	isomer	NN	O
15a	15a	NNS	O
and	and	CC	O
trans	tran	NNS	O
-	-	NNS	O
isomers	isomer	NNS	O
15b	15b	NNS	O
by	by	IN	O
the	the	DT	O
treatment	treatment	NN	O
with	with	IN	O
ethyl	ethyl	NNP	O
acetate	acetate	NNP	O
.	.	.	O

15a	15a	NNS	O
and	and	CC	O
15b	15b	NNS	O
exhibited	exhibit	VBD	O
greatly	greatly	RB	O
different	different	JJ	O
solubility	solubility	NN	O
for	for	IN	O
ethyl	ethyl	NN	O
acetate	acetate	NNP	O
,	,	,	O
and	and	CC	O
were	be	VBD	O
soluble	soluble	JJ	O
and	and	CC	O
insoluble	insoluble	JJ	O
for	for	IN	O
ethyl	ethyl	NN	O
acetate	acetate	NNP	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

Hydrolysis	hydrolysis	NN	O
of	of	IN	O
15a	15a	NNS	O
and	and	CC	O
15b	15b	NNS	O
afforded	afford	VBD	O
cis	cis	NN	O
isomer	isomer	NN	O
17a	17a	NNS	O
and	and	CC	O
trans	trans	NNPS	O
isomer	isomer	NN	O
17b	17b	NNS	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

Reagents	reagent	NNS	O
and	and	CC	O
conditions	condition	NNS	O
:	:	:	O
THF	THF	NNP	O
,	,	,	O
rt	rt	NNP	O
;	;	:	O
separation	separation	NN	O
by	by	IN	O
using	use	VBG	O
ethyl	ethyl	NN	O
acetate	acetate	NN	O
at	at	IN	O
60â70âÂ	60â70ââ	CD	O
°	°	,	O
C	C	NNP	O
;	;	:	O
filtrate	filtrate	JJ	O
for	for	IN	O
15a	15a	NNS	O
and	and	CC	O
solid	solid	JJ	O
for	for	IN	O
15b	15b	NNS	O
;	;	:	O
NaOH	NaOH	NNP	O
,	,	,	O
THF	THF	NNP	O
/	/	SYM	O
MeOH	MeOH	NNP	O
/	/	SYM	O
H2O	h2o	CD	O
;	;	:	O
1âM	1âm	CD	O
NaOH	NaOH	NNP	O
,	,	,	O
MeOH	MeOH	NNP	O
,	,	,	O
rt	rt	NNP	O
.	.	NNP	O

DGAT-1	DGAT-1	NNP	O
inhibitors	inhibitor	NNS	O
and	and	CC	O
their	-PRON-	PRP$	O
inÂ	inâ	JJ	O
vitro	vitro	FW	O
data	datum	NNS	O
.	.	.	O

Data	datum	NNS	O
present	present	VBP	O
mean	mean	JJ	O
values	value	NNS	O
.	.	.	O

Interestingly	interestingly	RB	O
,	,	,	O
the	the	DT	O
isomers	isomer	NNS	O
17a	17a	NNS	O
and	and	CC	O
17b	17b	NNS	O
were	be	VBD	O
more	more	RBR	O
potent	potent	JJ	O
than	than	IN	O
mixture	mixture	NN	O
14i	14i	NNS	O
,	,	,	O
and	and	CC	O
even	even	RB	O
compound	compound	VBP	O
2	2	CD	O
,	,	,	O
in	in	IN	O
SF9	SF9	NNP	O
cells	cell	NNS	O
.	.	.	O

However	however	RB	O
,	,	,	O
pharmacokinetic	pharmacokinetic	JJ	O
studies	study	NNS	O
demonstrated	demonstrate	VBD	O
that	that	IN	O
cis	cis	NN	O
-	-	HYPH	O
isomer	isomer	NN	O
17a	17a	NNS	O
had	have	VBD	O
a	a	DT	O
much	much	RB	O
better	well	JJR	O
profile	profile	NN	O
than	than	IN	O
trans	trans	JJ	O
-	-	JJ	O
isomer	isomer	JJ	O
17b	17b	NNS	O
.	.	.	O

17a	17a	NNS	O
had	have	VBD	O
a	a	DT	O
shorter	short	JJR	O
half	half	JJ	O
-	-	HYPH	O
life	life	NN	O
1.2âh	1.2âh	CD	O
,	,	,	O
but	but	CC	O
had	have	VBD	O
much	much	RB	O
better	well	JJR	O
bioavailability	bioavailability	NN	O
,	,	,	O
compared	compare	VBN	O
to	to	IN	O
17b	17b	NNS	O
.	.	.	O

In	in	IN	O
enzymatic	enzymatic	JJ	O
assays	assay	NNS	O
,	,	,	O
17a	17a	NNS	O
had	have	VBD	O
an	an	DT	O
IC50	IC50	NNP	O
of	of	IN	O
61ânM	61ânM	NNP	O
for	for	IN	O
DGAT-1	DGAT-1	NNS	O
and	and	CC	O
displayed	display	VBD	O
high	high	JJ	O
off	off	IN	O
-	-	HYPH	O
target	target	NN	O
selectivity	selectivity	NN	O
against	against	IN	O
DGAT-2	dgat-2	NN	O
,	,	,	O
acyl	acyl	NN	O
-	-	HYPH	O
coenzyme	coenzyme	NNS	O
A	a	NN	O
:	:	:	O
cholesterol	cholesterol	NN	O
acyltransferases	acyltransferase	NNS	O
.	.	.	O

ACATs	acat	NNS	O
have	have	VBP	O
sequence	sequence	NN	O
homology	homology	NN	O
to	to	IN	O
DGAT-1	dgat-1	VB	O
and	and	CC	O
play	play	VB	O
essential	essential	JJ	O
roles	role	NNS	O
in	in	IN	O
cholesterol	cholesterol	NN	O
homeostasis	homeostasis	NN	B
.	.	.	O

17b	17b	NNS	O
was	be	VBD	O
not	not	RB	O
explored	explore	VBN	O
in	in	IN	O
the	the	DT	O
enzymatic	enzymatic	JJ	O
assays	assay	NNS	O
due	due	JJ	O
to	to	IN	O
its	-PRON-	PRP$	O
poor	poor	JJ	O
pharmacokinetic	pharmacokinetic	JJ	O
profile	profile	NN	O
.	.	.	O

Enzyme	Enzyme	NNS	O
and	and	CC	O
cellular	cellular	JJ	O
inhibitory	inhibitory	NN	O
potencies	potency	NNS	O
for	for	IN	O
selected	select	VBN	O
compounds	compound	NNS	O
.	.	.	O

Pharmacokinetic	pharmacokinetic	JJ	O
profiles	profile	NNS	O
of	of	IN	O
compounds	compound	NNS	O
17a	17a	NNS	O
,	,	,	O
17b	17b	CD	O
in	in	IN	O
ICR	ICR	NNP	O
mice.aAll	mice.aall	JJ	O
parameters	parameter	NNS	O
were	be	VBD	O
determined	determine	VBN	O
after	after	IN	O
oral	oral	JJ	O
administration	administration	NN	O
10âmg	10âmg	CD	O
/	/	SYM	O
kg	kg	NNP	O
,	,	,	O
nâ=â3	nâ=â3	NNP	O
and	and	CC	O
intravenous	intravenous	JJ	O
injection	injection	NN	O
3âmg	3âmg	NNS	O
/	/	SYM	O
kg	kg	NNS	O
,	,	,	O
nâ=â2	nâ=â2	NNP	O
in	in	IN	O
ICR	ICR	NNP	O
mice	mouse	NNS	O
;	;	:	O
both	both	DT	O
compounds	compound	NNS	O
were	be	VBD	O
dissolved	dissolve	VBN	O
in	in	IN	O
a	a	DT	O
vehicle	vehicle	NN	O
solution	solution	NN	O
of	of	IN	O
DMSO	DMSO	NNP	O
/	/	SYM	O
Tween80	Tween80	NNP	O
/	/	SYM	O
saline	saline	NN	O
for	for	IN	O
iv	iv	NNP	O
.	.	NNP	O

,	,	,	O
and	and	CC	O
0.5	0.5	CD	O
%	%	NN	O
methylcellulose/0.5	methylcellulose/0.5	NNP	O
%	%	NN	O
Tween80	Tween80	NNP	O
in	in	IN	O
distilled	distilled	JJ	O
water	water	NN	O
for	for	IN	O
oral	oral	JJ	O
administration	administration	NN	O
.	.	.	O

Data	datum	NNS	O
represent	represent	VBP	O
mean	mean	JJ	O
values	value	NNS	O
.	.	.	O

Considering	consider	VBG	O
potency	potency	NN	O
,	,	,	O
selectivity	selectivity	NN	O
,	,	,	O
and	and	CC	O
pharmacokinetic	pharmacokinetic	JJ	O
profiles	profile	NNS	O
,	,	,	O
17a	17a	NNS	O
was	be	VBD	O
investigated	investigate	VBN	O
for	for	IN	O
further	further	JJ	O
pharmacokinetic	pharmacokinetic	JJ	O
properties	property	NNS	O
in	in	IN	O
four	four	CD	O
species	specie	NNS	O
,	,	,	O
and	and	CC	O
results	result	NNS	O
are	be	VBP	O
summarised	summarise	VBN	O
in	in	IN	O
Tables	Tables	NNP	O
4	4	CD	O
and	and	CC	O
5	5	CD	O
.	.	.	O

17a	17a	NNS	O
exhibited	exhibit	VBD	O
low	low	JJ	O
to	to	TO	O
moderate	moderate	JJ	O
clearance	clearance	NN	O
and	and	CC	O
acceptable	acceptable	JJ	O
oral	oral	JJ	O
bioavailability	bioavailability	NN	O
in	in	IN	O
rat	rat	NN	O
and	and	CC	O
dog	dog	NN	O
.	.	.	O

Oral	oral	JJ	O
pharmacokinetic	pharmacokinetic	JJ	O
profile	profile	NN	O
of	of	IN	O
17a	17a	NNS	O
in	in	IN	O
rat	rat	NN	O
and	and	CC	O
dog	dog	NN	O
.	.	.	O

Dose	dose	NN	O
;	;	:	O
3âmg	3âmg	NNS	O
/	/	SYM	O
kg	kg	NNS	O
for	for	IN	O
iv	iv	NNP	O
,	,	,	O
10âmg	10âmg	NNP	O
/	/	SYM	O
kg	kg	NNP	O
for	for	IN	O
po	po	NNP	O
.	.	NNP	O

;	;	:	O
Vehicle	vehicle	NN	O
:	:	:	O
DMSO	DMSO	NNP	O
/	/	SYM	O
Tween80	Tween80	NNP	O
/	/	SYM	O
saline	saline	NN	O
for	for	IN	O
iv	iv	NNP	O
.	.	.	O

;	;	:	O
0.5	0.5	CD	O
%	%	NN	O
methylcellulose/0.5	methylcellulose/0.5	NNP	O
%	%	NN	O
Twee80	Twee80	NNP	O
in	in	IN	O
distilled	distil	VBN	O
water	water	NN	O
for	for	IN	O
po	po	NN	O
.	.	.	O

Dose	dose	NN	O
:	:	:	O
1âmg	1âmg	CD	O
/	/	SYM	O
kg	kg	NNS	O
for	for	IN	O
iv	iv	NNP	O
,	,	,	O
3âmg	3âmg	NNP	O
/	/	SYM	O
kg	kg	NNS	O
for	for	IN	O
po	po	NNP	O
.	.	NNP	O

;	;	:	O
Vehicle	vehicle	NN	O
:	:	:	O
DMSO	DMSO	NNP	O
/	/	SYM	O
Tween80	Tween80	NNP	O
/	/	SYM	O
saline	saline	NN	O
for	for	IN	O
iv	iv	NN	O
;	;	:	O
0.5	0.5	CD	O
%	%	NN	O
methylcellulose/0.5	methylcellulose/0.5	NNP	O
%	%	NN	O
Tween80	Tween80	NNP	O
in	in	IN	O
distilled	distilled	JJ	O
water	water	NN	O
for	for	IN	O
po	po	NNP	O
.	.	.	O

In	in	IN	O
vitro	vitro	FW	O
microsomal	microsomal	JJ	O
stability	stability	NN	O
and	and	CC	O
cytochrome	cytochrome	VB	O
P450	p450	NN	O
inhibition	inhibition	NN	O
assay	assay	NN	O
of	of	IN	O
compound	compound	NN	O
17a	17a	NNS	O
.	.	.	O

Remaining	remain	VBG	O
percent	percent	NN	O
of	of	IN	O
metabolism	metabolism	NN	O
by	by	IN	O
incubation	incubation	NN	O
of	of	IN	O
the	the	DT	O
parent	parent	NN	O
molecule	molecule	NN	O
5âÎ¼M	5âî¼m	CD	O
with	with	IN	O
liver	liver	NN	O
microsomes	microsome	NNS	O
of	of	IN	O
mouse	mouse	NN	O
,	,	,	O
rat	rat	NN	O
,	,	,	O
dog	dog	NN	O
,	,	,	O
and	and	CC	O
human	human	NN	O
for	for	IN	O
60âmin	60âmin	CD	O
.	.	.	O

Data	datum	NNS	O
were	be	VBD	O
analysed	analyse	VBN	O
by	by	IN	O
a	a	DT	O
fluorescence	fluorescence	NN	O
detection	detection	NN	O
method.17a	method.17a	RB	O
exhibited	exhibit	VBN	O
durable	durable	JJ	O
metabolic	metabolic	JJ	O
stabilities	stability	NNS	O
,	,	,	O
as	as	IN	O
shown	show	VBN	O
in	in	IN	O
Table	table	NN	O
5	5	CD	O
.	.	.	O

In	in	IN	O
particular	particular	JJ	O
,	,	,	O
17a	17a	CD	O
was	be	VBD	O
metabolically	metabolically	RB	O
stable	stable	JJ	O
in	in	IN	O
four	four	CD	O
species	specie	NNS	O
:	:	:	O
human	human	JJ	O
,	,	,	O
dog	dog	NN	O
,	,	,	O
rat	rat	NN	O
,	,	,	O
and	and	CC	O
mouse	mouse	NN	O
.	.	.	O

Further	further	JJ	O
evaluation	evaluation	NN	O
of	of	IN	O
17a	17a	NNS	O
was	be	VBD	O
carried	carry	VBN	O
out	out	RP	O
for	for	IN	O
inhibition	inhibition	NN	O
of	of	IN	O
clinically	clinically	RB	O
relevant	relevant	JJ	O
cytochrome	cytochrome	JJ	O
450	450	CD	O
isoforms	isoform	NNS	O
.	.	.	O

No	no	DT	O
significant	significant	JJ	O
inhibition	inhibition	NN	O
by	by	IN	O
17a	17a	CD	O
was	be	VBD	O
observed	observe	VBN	O
.	.	.	O

Thus	thus	RB	O
,	,	,	O
17a	17a	NNS	O
would	would	MD	O
be	be	VB	O
very	very	RB	O
unlikely	unlikely	JJ	O
to	to	TO	O
affect	affect	VB	O
the	the	DT	O
pharmacokinetics	pharmacokinetic	NNS	O
of	of	IN	O
other	other	JJ	O
drugs	drug	NNS	O
.	.	.	O

To	to	TO	O
determine	determine	VB	O
inÂ	inÂ	NNP	O
vivo	vivo	NNP	O
efficacy	efficacy	NN	O
,	,	,	O
we	-PRON-	PRP	O
evaluated	evaluate	VBD	O
the	the	DT	O
activity	activity	NN	O
of	of	IN	O
17a	17a	NNS	O
against	against	IN	O
serum	serum	NN	O
TAG	TAG	NNP	O
level	level	NN	O
induced	induce	VBN	O
by	by	IN	O
the	the	DT	O
oral	oral	NNP	O
administration	administration	NN	O
of	of	IN	O
corn	corn	NN	O
oil	oil	NN	O
,	,	,	O
since	since	IN	O
intestinal	intestinal	JJ	O
targeted	target	VBN	O
DGAT-1	DGAT-1	NNS	O
inhibition	inhibition	NN	O
results	result	NNS	O
in	in	IN	O
a	a	DT	O
reduced	reduce	VBN	O
serum	serum	NN	O
TAG	TAG	VBN	O
level	level	NN	B
.	.	.	O

17a	17a	NNS	O
was	be	VBD	O
orally	orally	RB	O
administered	administer	VBN	O
to	to	IN	O
ICR	ICR	NNP	O
mice	mouse	NNS	O
at	at	IN	O
3âmg	3âmg	CD	O
/	/	SYM	O
kg	kg	NNS	O
or	or	CC	O
to	to	IN	O
dogs	dog	NNS	O
at	at	IN	O
1âmg	1âmg	CD	O
/	/	SYM	O
kg	kg	NNS	O
before	before	IN	O
administration	administration	NN	O
of	of	IN	O
corn	corn	NN	O
oil	oil	NN	O
.	.	.	O

As	as	IN	O
shown	show	VBN	O
in	in	IN	O
Figure	Figure	NNP	O
3	3	CD	O
,	,	,	O
17a	17a	NNS	O
showed	show	VBD	O
significant	significant	JJ	O
activity	activity	NN	O
,	,	,	O
as	as	RB	O
potent	potent	JJ	O
as	as	IN	O
compound	compound	NN	O
2	2	CD	O
,	,	,	O
in	in	IN	O
reducing	reduce	VBG	O
plasma	plasma	NN	O
TAG	TAG	NNP	O
level	level	NN	O
.	.	.	O

Effect	effect	NN	O
of	of	IN	O
17a	17a	NNS	O
in	in	IN	O
the	the	DT	O
oral	oral	JJ	O
lipid	lipid	NN	O
tolerance	tolerance	NN	O
test	test	NN	O
nâ=â5	nâ=â5	NNP	O
,	,	,	O
*	*	NFP	O
*	*	NFP	O
*	*	NFP	O
pâ<â.001	pâ<â.001	NN	O
.	.	.	O

Serum	Serum	NNP	O
TG	TG	NNP	O
concentration	concentration	NN	O
was	be	VBD	O
measured	measure	VBN	O
before	before	RB	O
and	and	CC	O
1	1	CD	O
,	,	,	O
2	2	CD	O
,	,	,	O
and	and	CC	O
4âh	4âh	CD	O
after	after	IN	O
oral	oral	JJ	O
administration	administration	NN	O
of	of	IN	O
corn	corn	NN	O
oil	oil	NN	O
in	in	IN	O
ICR	ICR	NNP	O
mice	mouse	NNS	O
treated	treat	VBN	O
with	with	IN	O
17a	17a	NNS	O
3âmg	3âmg	CD	O
/	/	SYM	O
kg	kg	NNS	O
or	or	CC	O
2	2	CD	O
1âmg	1âmg	CD	O
/	/	SYM	O
kg	kg	NNS	O
.	.	.	O

Vehicle	vehicle	NN	O
for	for	IN	O
2	2	CD	O
:	:	:	O
0.5	0.5	CD	O
%	%	NN	O
methylcellulose/0.5	methylcellulose/0.5	NNP	O
%	%	NN	O
Tween80	Tween80	NNP	O
in	in	IN	O
distilled	distilled	JJ	O
water	water	NN	O
,	,	,	O
vehicle	vehicle	NN	O
for	for	IN	O
17a	17a	CD	O
:	:	:	O
0.5	0.5	CD	O
%	%	NN	O
Tween80	Tween80	NNP	O
in	in	IN	O
distilled	distilled	JJ	O
water	water	NN	O
.	.	.	O

Effect	effect	NN	O
of	of	IN	O
17a	17a	NNS	O
in	in	IN	O
a	a	DT	O
canine	canine	JJ	O
oral	oral	JJ	O
lipid	lipid	NN	O
tolerance	tolerance	NN	O
test	test	NN	O
nâ=â2	nâ=â2	NNP	O
,	,	,	O
*	*	NFP	O
pâ<â.05	pâ<â.05	FW	O
;	;	:	O
*	*	NFP	O
*	*	NFP	O
*	*	NFP	O
pâ<â.001	pâ<â.001	NN	O
.	.	.	O

The	the	DT	O
dog	dog	NN	O
was	be	VBD	O
treated	treat	VBN	O
with	with	IN	O
17a	17a	NNPS	O
po	po	NNP	O
.	.	NNP	O

1âmg	1âmg	CD	O
/	/	SYM	O
kg	kg	NNS	O
or	or	CC	O
2	2	CD	O
po	po	NN	O
.	.	NNP	O

1âmg	1âmg	CD	O
/	/	SYM	O
kg	kg	NNS	O
before	before	IN	O
oral	oral	NNP	O
administration	administration	NNP	O
of	of	IN	O
corn	corn	NN	O
oil	oil	NN	O
.	.	.	O

Vehicle	vehicle	NN	O
for	for	IN	O
2	2	CD	O
:	:	:	O
0.5	0.5	CD	O
%	%	NN	O
methylcellulose/0.5	methylcellulose/0.5	NNP	O
%	%	NN	O
Tween80	Tween80	NNP	O
in	in	IN	O
distilled	distilled	JJ	O
water	water	NN	O
,	,	,	O
vehicle	vehicle	NN	O
for	for	IN	O
17a	17a	CD	O
:	:	:	O
0.5	0.5	CD	O
%	%	NN	O
Tween80	Tween80	NNP	O
in	in	IN	O
distilled	distilled	JJ	O
water	water	NN	O
.	.	.	O

In	in	IN	O
addition	addition	NN	O
,	,	,	O
tissue	tissue	NN	O
distribution	distribution	NN	O
of	of	IN	O
17a	17a	NNS	O
was	be	VBD	O
investigated	investigate	VBN	O
.	.	.	O

17a	17a	NNS	O
was	be	VBD	O
orally	orally	RB	O
administered	administer	VBN	O
to	to	IN	O
mice	mouse	NNS	O
at	at	IN	O
30âmg	30âmg	CD	O
/	/	SYM	O
kg	kg	NNS	O
,	,	,	O
and	and	CC	O
2	2	CD	O
was	be	VBD	O
administrated	administrate	VBN	O
as	as	IN	O
a	a	DT	O
positive	positive	JJ	O
control	control	NN	O
.	.	.	O

The	the	DT	O
concentration	concentration	NN	O
levels	level	NNS	O
of	of	IN	O
17a	17a	NNS	O
in	in	IN	O
the	the	DT	O
liver	liver	NN	O
and	and	CC	O
small	small	JJ	O
intestine	intestine	NN	O
were	be	VBD	O
much	much	RB	O
higher	high	JJR	O
than	than	IN	O
in	in	IN	O
other	other	JJ	O
tissues	tissue	NNS	O
,	,	,	O
indicating	indicate	VBG	O
that	that	IN	O
liver	liver	NN	O
and	and	CC	O
small	small	JJ	O
intestine	intestine	NN	O
are	be	VBP	O
the	the	DT	O
main	main	JJ	O
target	target	NN	O
organs	organ	NNS	O
of	of	IN	O
17a	17a	NNS	O
,	,	,	O
while	while	IN	O
2	2	CD	O
showed	show	VBD	O
much	much	JJ	O
high	high	JJ	O
concentrations	concentration	NNS	O
in	in	IN	O
the	the	DT	O
liver	liver	NN	O
and	and	CC	O
large	large	JJ	O
intestine	intestine	NN	O
.	.	.	O

Analysis	analysis	NN	O
of	of	IN	O
tissue	tissue	NN	O
-	-	HYPH	O
to	to	IN	O
-	-	HYPH	O
plasma	plasma	NN	O
ratios	ratio	NNS	O
indicated	indicate	VBD	O
that	that	IN	O
17a	17a	CD	O
had	have	VBD	O
favourable	favourable	JJ	O
distributions	distribution	NNS	O
in	in	IN	O
the	the	DT	O
liver	liver	NN	O
and	and	CC	O
small	small	JJ	O
intestine	intestine	NN	O
.	.	.	O

Significant	significant	JJ	O
activity	activity	NN	O
of	of	IN	O
17a	17a	NNS	O
in	in	IN	O
the	the	DT	O
OLTT	OLTT	NNP	O
appeared	appear	VBD	O
to	to	TO	O
result	result	VB	O
from	from	IN	O
high	high	JJ	O
concentration	concentration	NN	O
in	in	IN	O
the	the	DT	O
small	small	JJ	O
intestine	intestine	NN	O
,	,	,	O
even	even	RB	O
though	though	IN	O
bioavailability	bioavailability	NN	O
of	of	IN	O
17a	17a	CD	O
was	be	VBD	O
not	not	RB	O
great	great	JJ	O
in	in	IN	O
mice	mouse	NNS	O
.	.	.	O

This	this	DT	O
result	result	NN	O
could	could	MD	O
be	be	VB	O
proof	proof	NN	O
of	of	IN	O
a	a	DT	O
pharmacokineticâpharmacodynamic	pharmacokineticâpharmacodynamic	JJ	O
correlation	correlation	NN	O
.	.	.	O

Tissue	tissue	NN	O
distribution	distribution	NN	O
of	of	IN	O
17a	17a	NNS	O
in	in	IN	O
mice	mouse	NNS	O
.	.	.	O

17a	17a	NNS	O
and	and	CC	O
2	2	CD	O
were	be	VBD	O
orally	orally	RB	O
administered	administer	VBN	O
to	to	IN	O
ICR	ICR	NNP	O
mice	mouse	NNS	O
at	at	IN	O
30âmg	30âmg	CD	O
/	/	SYM	O
kg	kg	NNP	O
nâ=â3	nâ=â3	NNP	O
.	.	.	O

AUC	AUC	NNP	O
values	value	NNS	O
of	of	IN	O
17a	17a	NNS	O
and	and	CC	O
2	2	CD	O
in	in	IN	O
indicated	indicate	VBN	O
tissues	tissue	NNS	O
.	.	.	O

Each	each	DT	O
bar	bar	NN	O
shows	show	VBZ	O
AUC	AUC	NNP	O
obtained	obtain	VBN	O
from	from	IN	O
concentrations	concentration	NNS	O
measured	measure	VBN	O
at	at	IN	O
0.5âh	0.5âh	CD	O
,	,	,	O
1âh	1âh	CD	O
,	,	,	O
2âh	2âh	CD	O
,	,	,	O
4âh	4âh	CD	O
,	,	,	O
and	and	CC	O
24âh	24âh	CD	O
after	after	IN	O
dosing	dose	VBG	O
.	.	.	O

Data	datum	NNS	O
represent	represent	VBP	O
mean	mean	JJ	O
value	value	NN	O
.	.	.	O

Tissue	tissue	NN	O
-	-	HYPH	O
to	to	IN	O
-	-	HYPH	O
plasma	plasma	NN	O
ratio	ratio	NN	O
of	of	IN	O
17a	17a	NNS	O
and	and	CC	O
2	2	CD	O
.	.	.	O

S.	S.	NNP	O
I.	I.	NNP	O
:	:	:	O
small	small	JJ	O
intestine	intestine	NN	O
,	,	,	O
L.	L.	NNP	O
I.	I.	NNP	O
:	:	:	O
large	large	JJ	O
intestine	intestine	NN	O
.	.	.	O

We	-PRON-	PRP	O
found	find	VBD	O
that	that	IN	O
a	a	DT	O
novel	novel	JJ	O
series	series	NN	O
of	of	IN	O
thienopyrimidine	thienopyrimidine	NN	O
derivatives	derivative	NNS	O
had	have	VBD	O
potent	potent	JJ	O
DGAT-1	DGAT-1	NNS	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
.	.	.	O

A	a	DT	O
representative	representative	JJ	O
compound	compound	NN	O
,	,	,	O
cis	cis	NN	O
-	-	HYPH	O
isomer	isomer	NN	O
17a	17a	NNS	O
showed	show	VBD	O
potent	potent	JJ	O
DGAT-1	DGAT-1	NNS	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
,	,	,	O
metabolic	metabolic	JJ	O
stability	stability	NN	O
in	in	IN	O
four	four	CD	O
species	specie	NNS	O
,	,	,	O
an	an	DT	O
acceptable	acceptable	JJ	O
pharmacokinetic	pharmacokinetic	JJ	O
profile	profile	NN	O
in	in	IN	O
rodents	rodent	NNS	O
and	and	CC	O
dogs	dog	NNS	O
,	,	,	O
and	and	CC	O
a	a	DT	O
significant	significant	JJ	O
reduction	reduction	NN	O
of	of	IN	O
TAG	TAG	NNP	O
in	in	IN	O
the	the	DT	O
OLTT	OLTT	NNP	O
in	in	IN	O
mice	mouse	NNS	O
and	and	CC	O
dogs	dog	NNS	O
.	.	.	O

In	in	IN	O
a	a	DT	O
tissue	tissue	NN	O
-	-	HYPH	O
distribution	distribution	NN	O
study	study	NN	O
,	,	,	O
17a	17a	NNS	O
was	be	VBD	O
mainly	mainly	RB	O
distributed	distribute	VBN	O
to	to	IN	O
the	the	DT	O
liver	liver	NN	O
and	and	CC	O
small	small	JJ	O
intestine	intestine	NN	O
.	.	.	O

Therefore	therefore	RB	O
,	,	,	O
17a	17a	NNS	O
could	could	MD	O
be	be	VB	O
a	a	DT	O
candidate	candidate	NN	O
with	with	IN	O
considerable	considerable	JJ	O
potential	potential	NN	O
and	and	CC	O
deserves	deserve	NNS	O
for	for	IN	O
further	further	JJ	O
investigation	investigation	NN	O
.	.	.	O

